168 related articles for article (PubMed ID: 24866575)
1. GH receptor isoforms and skeletal fragility in acromegaly.
Mormando M; Nasto LA; Bianchi A; Mazziotti G; Giampietro A; Pola E; Pontecorvi A; Giustina A; De Marinis L
Eur J Endocrinol; 2014 Aug; 171(2):237-45. PubMed ID: 24866575
[TBL] [Abstract][Full Text] [Related]
2. Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.
Pontes J; Madeira M; Lima CHA; Ogino LL; de Paula Paranhos Neto F; de Mendonça LMC; Farias MLF; Kasuki L; Gadelha MR
J Endocrinol Invest; 2020 Feb; 43(2):163-171. PubMed ID: 31392573
[TBL] [Abstract][Full Text] [Related]
3. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.
Mercado M; González B; Sandoval C; Esquenazi Y; Mier F; Vargas G; de los Monteros AL; Sosa E
J Clin Endocrinol Metab; 2008 Sep; 93(9):3411-5. PubMed ID: 18611972
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M; Chiloiro S; Bianchi A; Giampietro A; Angelini F; Tartaglione L; Nasto L; Milardi D; Formenti AM; Giustina A; De Marinis L
Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620
[TBL] [Abstract][Full Text] [Related]
6. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.
Wassenaar MJ; Biermasz NR; Pereira AM; van der Klaauw AA; Smit JW; Roelfsema F; van der Straaten T; Cazemier M; Hommes DW; Kroon HM; Kloppenburg M; Guchelaar HJ; Romijn JA
J Clin Endocrinol Metab; 2009 Dec; 94(12):4671-8. PubMed ID: 19864451
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
[TBL] [Abstract][Full Text] [Related]
8. The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility.
Chiloiro S; Mirra F; Federico D; Giampietro A; Visconti F; Rossi L; Pontecorvi A; De Marinis L; Bianchi A
Protein Pept Lett; 2020; 27(12):1260-1267. PubMed ID: 32543356
[TBL] [Abstract][Full Text] [Related]
9. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
[TBL] [Abstract][Full Text] [Related]
10. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
11. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
[TBL] [Abstract][Full Text] [Related]
14. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
15. Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.
Topsakal S; Akin F; Turgut S; Yerlikaya E; Yaylali GF
Adv Clin Exp Med; 2017; 26(2):281-286. PubMed ID: 28791847
[TBL] [Abstract][Full Text] [Related]
16. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly.
Wassenaar MJ; Biermasz NR; Hamdy NA; Zillikens MC; van Meurs JB; Rivadeneira F; Hofman A; Uitterlinden AG; Stokkel MP; Roelfsema F; Kloppenburg M; Kroon HM; Romijn JA; Pereira AM
Eur J Endocrinol; 2011 Apr; 164(4):475-83. PubMed ID: 21257726
[TBL] [Abstract][Full Text] [Related]
18. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
19. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study.
Claessen KM; Kroon HM; Pereira AM; Appelman-Dijkstra NM; Verstegen MJ; Kloppenburg M; Hamdy NA; Biermasz NR
J Clin Endocrinol Metab; 2013 Dec; 98(12):4808-15. PubMed ID: 24081732
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fracture assessment in acromegaly.
Madeira M; Neto LV; Torres CH; de Mendonça LM; Gadelha MR; de Farias ML
J Clin Densitom; 2013; 16(2):238-43. PubMed ID: 22884713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
